Amgen Inc. (AMGN) - Financial and Strategic SWOT Analysis Review

Date: March 15, 2016
Pages: 83
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A0EFA65379DEN
Leaflet:

Download PDF Leaflet

Amgen Inc. (AMGN) - Financial and Strategic SWOT Analysis Review
Amgen Inc. (AMGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Amgen Inc. (Amgen) is a biotechnology company. It undertakes the discovery, development, manufacture and commercialization of innovative human therapeutics. The company products are used in the treatment of cancer, rheumatoid arthritis, kidney disease, bone disease and many other serious illnesses. Amgen’s R&D organization has expertise in multiple treatment modalities, antibodies, large-molecule proteins and small molecules. The company’s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidney disease and in cancer; and Prolia (denosumab) used in the treatment of osteoporosis in postmenopausal women among others. The company has research and development (R&D) facilities in the US, Canada, the UK, Germany and Iceland. Amgen is headquartered in Thousand Oaks, California, the US.

Amgen Inc. Key Recent Developments

Feb 12, 2016: West's Daikyo Crystal Zenith Cyclic Olefin Polymer Selected by Amgen
Jan 28, 2016: Amgen's 2015 Revenues Increased 8 Percent To $21.7 Billion And Adjusted Earnings Per Share Increased 19 Percent To $10.38
Jan 11, 2016: Historic National Coalition Formed to Accelerate Next Generation Immunotherapy in Cancer
Dec 22, 2015: Prime Therapeutics prefers both cholesterol lowering drugs Praluent and Repatha on its national drug list
Nov 05, 2015: Key Data For Amgen Medicines In Relapsed Multiple Myeloma And Acute Lymphoblastic Leukemia To Be Presented At ASH 2015

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Amgen Inc. - Key Facts
Amgen Inc. - Key Employees
Amgen Inc. - Key Employee Biographies
Amgen Inc. - Major Products and Services
Amgen Inc. - Pharmaceutical Pipeline Products Data
Amgen Inc., Pipeline Products by Therapy Area
Amgen Inc., Pipeline Products by Development Phase
Amgen Inc. - History
Amgen Inc. - Company Statement
Amgen Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Amgen Inc. - Key Manufacturing Facilities
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Amgen Inc. - Business Description
Amgen Inc. - Corporate Strategy
Amgen Inc. - SWOT Analysis
SWOT Analysis - Overview
Amgen Inc. - Strengths
Strength - Research and Development
Strength - Products Covering Various Therapeutic Areas
Strength - Operational Performance
Amgen Inc. - Weaknesses
Weakness - Patent Infringement Lawsuit
Weakness - Termination of Development Programs
Amgen Inc. - Opportunities
Opportunity - Product Pipeline
Opportunity - Branded Biosimilars Growth Potential
Opportunity - Strategic Initiatives
Amgen Inc. - Threats
Threat - Dependence on Wholesale Distributors
Threat - Stiff Competition
Threat - Influx of Generics
Amgen Inc. - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Amgen Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Amgen Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Amgen Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
Amgen Inc., Medical Equipment, Deals By Type, 2010 to YTD 2016
Amgen Inc., Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 12, 2016: West's Daikyo Crystal Zenith Cyclic Olefin Polymer Selected by Amgen
Jan 28, 2016: Amgen's 2015 Revenues Increased 8 Percent To $21.7 Billion And Adjusted Earnings Per Share Increased 19 Percent To $10.38
Jan 11, 2016: Historic National Coalition Formed to Accelerate Next Generation Immunotherapy in Cancer
Dec 22, 2015: Prime Therapeutics prefers both cholesterol lowering drugs Praluent and Repatha on its national drug list
Nov 05, 2015: Key Data For Amgen Medicines In Relapsed Multiple Myeloma And Acute Lymphoblastic Leukemia To Be Presented At ASH 2015
Nov 04, 2015: Amgen Highlights Data To Be Presented At 2015 American College Of Rheumatology And Association For Rheumatology Health Professionals Annual Meeting
Oct 28, 2015: Amgen's Third Quarter 2015 Revenues Increased 14 Percent To $5.7 Billion And Adjusted Earnings Per Share (EPS) Increased 18 Percent To $2.72
Oct 28, 2015: Amgen's Third Quarter 2015 Revenues Increased 14 Percent To $5.7 Billion And Adjusted Earnings Per Share Increased 18 Percent To $2.72
Oct 21, 2015: Amgen Foundation Announces New $4 Million Commitment to Bring Hands-On Biotechnology Labs to Secondary School Students
Oct 06, 2015: Express Scripts Includes Innovative Cholesterol-Lowering Drugs on National Preferred Formulary

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Amgen Inc., Key Facts
Amgen Inc., Key Employees
Amgen Inc., Key Employee Biographies
Amgen Inc., Major Products and Services
Amgen Inc., Number of Pipeline Products by Therapy Area
Amgen Inc., Number of Pipeline Products by Development Stage
Amgen Inc., Pipeline Products By Therapy Area and Development Phase
Amgen Inc., History
Amgen Inc., Other Locations
Amgen Inc., Subsidiaries
Amgen Inc., Key Manufacturing Facilities
Amgen Inc., Joint Venture
Amgen Inc., Key Competitors
Amgen Inc., Ratios based on current share price
Amgen Inc., Annual Ratios
Amgen Inc., Interim Ratios
Amgen Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Amgen Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Amgen Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
Amgen Inc., Medical Equipment, Deals By Type, 2010 to YTD 2016
Amgen Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Amgen Inc., Pipeline Products by Therapy Area
Amgen Inc., Pipeline Products by Development Phase
Amgen Inc., Performance Chart (2011 - 2015)
Amgen Inc., Ratio Charts
Amgen Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Amgen Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Amgen Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
Amgen Inc., Medical Equipment, Deals by Type, 2010 to YTD 2016
Skip to top


Ask Your Question

Amgen Inc. (AMGN) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: